Catastrophic adult-onset Still&apos;s disease as a distinct life-threatening clinical subset: case-control study with dimension reduction analysis

Atopic Dermatitis

Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis

JAMA Dermatol.

Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, Mastey V, Wei W, Eckert L, Chao J, Arnold RJG, Yu T, Vekeman F, Suárez-Fariñas M, Gadkari A

doi: 10.1001/jamadermatol.2018.

Rheumatoid Arthritis

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study

Ann Rheum Dis.

Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Pinto-Correia A, Otawa S, Lopez-Romero P, de la Torre I, Macias W, Rooney TP, Smolen JS

doi: 10.1136/annrheumdis-2018-

PsoriasisPsoriatic ArthritisSpinal Disorders

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

Ann Rheum Dis.

Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, Porter B, Das Gupta A, Pricop L, Fox T

doi: 10.1136/annrheumdis-2018-214273.

Autoimmune Disease

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis

Ann Rheum Dis

Akiyama S, Hamdeh S, Micic D, Sakuraba A

doi: 10.1136/annrheumdis-2020-218946

Atopic Dermatitis

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

Br J Dermatol.

Tsianakas A, Luger TA, Radin A

doi: 10.1111/bjd.15905.

Psoriasis

Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post-hoc analysis of the BRIDGE study

J Eur Acad Dermatol Venereol.

Van de Kerkhof PCM, Loewe R, Mrowietz U, Falques M, Pau-Charles I, Szepietowski JC

doi: 10.1111/jdv.15922.

Further Publications Immunology

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Lancet.

Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO

doi: 10.1016/S0140-6736(17)

Systemic Lupus Erythematosus

Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland

Swiss Med Wkly.

von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger PM, Vallelian F, Schaer DJ, Mueller RB

doi: 10.4414/smw.2019.20022.

Further Publications Rheumatology

Drug retention rates of biological agents in adult onset Still's disease

Semin Arthritis Rheum

Campochiaro C, Farina N, Tomelleri A, De Luca G, Baldissera E, Cavalli G, Dagna L

doi: 10.1016/j.semarthrit.2020.09.014

Dermatology · Immunology · Rheumatology

Catastrophic adult-onset Still's disease as a distinct life-threatening clinical subset: case-control study with dimension reduction analysis

Related content